Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Izalontamab Brengitecan · BMS-986507

Bispecific antibody · Cytotoxic, directed at EGFR and HER3 (ERBB3) · developed by BRISTOL MYERS SQUIBB

Phase 2/3 Most advanced trial

BMY Developer

2 Registered trials

What is Izalontamab Brengitecan?

Izalontamab brengitecan is a bispecific antibody-drug conjugate targeting EGFR and HER3, conjugated to Ed-04, a topoisomerase 1 inhibitor. Upon binding to EGFR and HER3 on cancer cells and internalization, Ed-04 is released to inhibit DNA topoisomerase I, causing cell cycle arrest and apoptosis. It is studied in lung cancer and breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: BMS-986507, Iza-bren
Drug type: Bispecific antibody
Targets: EGFR, HER3 (ERBB3), DNA topoisomerase I (TOP1) (secondary target)
Mechanism: Cytotoxic, directed at EGFR and HER3 (ERBB3)
Pathways: DNA replication inhibition, apoptosis
Therapy area: Oncology
Developer: BRISTOL MYERS SQUIBB (BMY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII: UC2FX6YY3P

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07100080	Phase 2/3	Non-Small Cell Lung Cancer	Recruiting	BMY
NCT06618287	Phase 1/2	Lung Cancer	Recruiting	BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast CancerLung CancerNon-Small Cell Lung Cancer

Other drugs acting on EGFR / ERBB3

Neratinib FDA approved Osimertinib FDA approved Actinium Ac 225 FPI-2068 Phase 1 ALX2004 Phase 1 BH-30643 Phase 1/2 CDX-3379 Phase 2 CUDC-101 Phase 1 EGFR-TKI inhibitor based on investigator's choice Phase 3 Enozertinib Phase 1/2 Ficerafusp Alfa Phase 2/3 Firmonertinib Phase 3 FPI-2053 Phase 1

More from BRISTOL MYERS SQUIBB

Apixaban FDA approved Belatacept FDA approved Deucravacitinib FDA approved Ipilimumab FDA approved Lisocabtagene Maraleucel FDA approved Luspatercept FDA approved Mavacamten FDA approved Nab-paclitaxel FDA approved Nivolumab FDA approved Ozanimod FDA approved Relatlimab FDA approved Repotrectinib FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Izalontamab Brengitecan

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z